Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Surgery. 2019 Sep 9;167(1):10–17. doi: 10.1016/j.surg.2019.03.031

Table 2.

Details and outcomes of patients with contralateral lobe PTC

Patient Multifocality Status Time to Contralateral Lobe PTC* (years) Management of Contralateral Lobe PTC Final Outcome - ATA response to treatment
1 MFD 1.1 Surgery NED - Unknown
2 UFD§ 1.3 Surgery NED - Excellent
3 UFD 3.0 Surgery NED - Unknown
4 UFD 3.0 Surgery NED - Excellent
5 UFD 3.5 Surgery NED - Unknown
6 UFD 4.9 Surgery NED - Unknown
7 UFD 6.1 Surgery NED - Unknown
8 MFD 10.6 Surgery NED - Excellent
9 UFD 11.3 Surgery NED - Indeterminate
10 MFD 11.9 Surgery NED - Unknown
11 UFD 12.9 Surgery NED - Indeterminate
12 MFD 13.3 Active Surveillance ALD - Structural Incomplete
13 UFD 13.5 Active Surveillance ALD - Structural Incomplete
14 MFD 23.5 Surgery NED - Indeterminate
*

PTC – Papillary Thyroid Carcinoma

ATA – American Thyroid Association

MFD – multifocal disease

§

UFD – unifocal disease

NED – no evidence of disease

ALD – alive with loco-regional disease